NCT00062244View on ClinicalTrials.gov

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2007

Conditions
Waldenström Macroglobulinemia
Interventions
BIOLOGICAL

oblimersen sodium

Given IV

Trial Locations (8)

20060

Howard University Hospital, Washington D.C.

48201

Barbara Ann Karmanos Cancer Institute, Detroit

53792

University of Wisconsin Hospital and Clinics, Madison

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

21201-1595

University of Maryland Greenebaum Cancer Center, Baltimore

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00062244 - Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter